Evidence was from an unpublished phase 3 study (n=343) in people with rheumatoid arthritis, which was included in the European public assessment report (EPAR) for Remsima (subcutaneous). For the ...

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, Inc. (KRX:068270) today announced that the company has completed Phase 3 clinical trial for ‘Remsima SC’, the subcutaneous (SC) version of Remsima®, ...

South Korean drug maker Celltrion said Tuesday its antibody biosimilar Remsima has received authorization from 100 countries worldwide, a feat achieved almost 10 years after its getting approval at ...

Celltrion Healthcare, Celltrion’s overseas sales and marketing unit, announced Monday that the company has launched its Remsima SC in Brazil, the largest pharmaceutical market in South America.

Celltrion Healthcare has today announced the launch of Remsima™ (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy ...

Celltrion's autoimmune disease treatment "Remsima (infliximab)" has surpassed 1 trillion won in annual sales for the second consecutive year, cementing its status as a global blockbuster. With the ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a Korean company to achieve blockbuster status, the biotech company said Wednesday ...

Remsima has demonstrated comparability to the reference product, Remicade, in terms of safety, efficacy, and quality. Mundipharma has launched the biosimilar version of infliximab (Remsima) in Germany ...

Please provide your email address to receive an email when new articles are posted on . A safety profile consistent with that of the historical safety data of Remicade was observed among patients with ...

Celltrion has launched the liquid formulation of 'Remsima' (active ingredient: infliximab) in Europe, aiming to strengthen its leadership in the infliximab market. The infliximab liquid formulation is ...

As with all biologic disease-modifying antirheumatic drugs (DMARDs) for ulcerative colitis and Crohn's disease, Remsima (subcutaneous) would be prescribed and started in secondary care ...